Examining the bleeding incidences associated with targeted therapies used in metastatic renal cell carcinoma.
Sign Up to like & getrecommendations! Published in 2017 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2017.10.014
Abstract: A systematic review was conducted to illustrate the bleeding risks associated with targeted therapies used in the treatment of metastatic renal cell carcinoma (mRCC). Eligible studies included phase II, III, or IV clinical trials using… read more here.
Keywords: renal cell; therapies used; associated targeted; metastatic renal ... See more keywords